Alan B. Slifka Foundation is currently accepting letters of intent on a rolling basis for research projects not exceeding $50,000 per year for up to two years. You may find more information here: https://slifkafoundation.org/biomedical-grants/sarcoma-research/
Alan B. Slifka Foundation is currently accepting letters of intent on a rolling basis for research projects not exceeding $50,000 per year for up to two years. You may find more information here: https://slifkafoundation.org/biomedical-grants/sarcoma-research/
MIB Agents Osteosarcoma Alliance is accepting applications for their OutSmarting Osteosarcoma 2025 grant cycle. Letters of intent for the OutSmarting Osteosarcoma Hero Award ($100,000/one year) and the OutSmarting Osteosarcoma Young Investigator Award ($50,000/one year) are due by October 25, 2024 (11:59pm ET). Awardees must be located at an institution within the US. You may find more information here: https://www.mibagents.org/research/outsmarting-osteosarcoma
MIB Agents Osteosarcoma Alliance is accepting applications for their OutSmarting Osteosarcoma 2025 grant cycle. Letters of intent for the OutSmarting Osteosarcoma Hero Award ($100,000/one year) and the OutSmarting Osteosarcoma Young Investigator Award ($50,000/one year) are due by October 25, 2024 (11:59pm ET). Awardees must be located at an institution within the US. You may find more information here: https://www.mibagents.org/research/outsmarting-osteosarcoma
Northwest Sarcoma Foundation is accepting proposals with a preference for investigators located in Alaska, Idaho, Montana, Oregon, and Washington. The deadline for applications is October 15, 2024 (5:00pm PT). You may find more information here: https://www.nwsarcoma.org/apply-for-research-grant
Northwest Sarcoma Foundation is accepting proposals with a preference for investigators located in Alaska, Idaho, Montana, Oregon, and Washington. The deadline for applications is October 15, 2024 (5:00pm PT). You may find more information here: https://www.nwsarcoma.org/apply-for-research-grant
The Sarcoma Foundation of America is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and clinical research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. This RFP is in support of our overall mission to fund research and increase awareness and advocacy for sarcoma patients and their families. The goal of the SFA grant program is to encourage research that results in improved therapeutic options for sarcoma patients. The SFA encourages applications in ALL areas of sarcoma research.
Learn more about SFA Research Grants here.
The Sarcoma Foundation of America is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and clinical research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. This RFP is in support of our overall mission to fund research and increase awareness and advocacy for sarcoma patients and their families. The goal of the SFA grant program is to encourage research that results in improved therapeutic options for sarcoma patients. The SFA encourages applications in ALL areas of sarcoma research.
Learn more about SFA Research Grants here.
Summer’s Way Foundation is currently accepting proposals for the Summers Way/Friends of TJ Young Investigator Grant to support scientists in the early stages of their careers, such as postdoctoral or clinical fellows. Applicants must not have achieved an appointment higher than than instructor and the grant program must have a focus on pediatric sarcoma. The deadline for applications is December 30, 2024 (11:59 PM ET). You may find more information here: https://summersway.org/researchers/young-investigator-grant-application
Subtypes: alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, alveolar soft part sarcoma, CIC-rearranged sarcoma, ewing sarcoma, DSRCT, extrarenal rhabdoid tumor, infantile fibrosarcoma, NTRK-rearranged spindle cell, rhabdomyosarcoma, round cell sarcoma with EWSR1-non-ets fusions, Sarcoma with BCOR alterations, spindle cell/sclerosing rhabdomyosarcoma, undifferentiated sarcoma
Summer’s Way Foundation is currently accepting proposals for the Summers Way/Friends of TJ Young Investigator Grant to support scientists in the early stages of their careers, such as postdoctoral or clinical fellows. Applicants must not have achieved an appointment higher than than instructor and the grant program must have a focus on pediatric sarcoma. The deadline for applications is December 30, 2024 (11:59 PM ET). You may find more information here: https://summersway.org/researchers/young-investigator-grant-application
Subtypes: alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, alveolar soft part sarcoma, CIC-rearranged sarcoma, ewing sarcoma, DSRCT, extrarenal rhabdoid tumor, infantile fibrosarcoma, NTRK-rearranged spindle cell, rhabdomyosarcoma, round cell sarcoma with EWSR1-non-ets fusions, Sarcoma with BCOR alterations, spindle cell/sclerosing rhabdomyosarcoma, undifferentiated sarcoma
The Sarcoma Foundation of America (SFA) is pleased to announce it is accepting applications for its Last Mile Research Grant. In its second year, the research funding opportunity provides one-year grants of $150,000, to support translational science research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. Completed applications must be submitted by February 3, 2025, at 5:00 pm EDT.
In support of our overall mission to fund research and increase awareness and advocacy for sarcoma patients and their families, the goal of the SFA grant program is to encourage research that results in improved therapeutic options for sarcoma patients.
Learn more about The Last Mile Research Award here.
The Sarcoma Foundation of America (SFA) is pleased to announce it is accepting applications for its Last Mile Research Grant. In its second year, the research funding opportunity provides one-year grants of $150,000, to support translational science research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. Completed applications must be submitted by February 3, 2025, at 5:00 pm EDT.
In support of our overall mission to fund research and increase awareness and advocacy for sarcoma patients and their families, the goal of the SFA grant program is to encourage research that results in improved therapeutic options for sarcoma patients.
Learn more about The Last Mile Research Award here.
The Osteosarcoma Institute is currently accepting letters of intent for Clinical Trials, Correlative Science, Preclinical/Translational, and High-Risk/High-Impact grant programs in osteosarcoma. The deadline for submission is October 31, 2024. Off-cycle applications may be considered on a case-by-case basis. You may find more information here: https://osinst.org/researchers/#grants.
The Osteosarcoma Institute is currently accepting letters of intent for Clinical Trials, Correlative Science, Preclinical/Translational, and High-Risk/High-Impact grant programs in osteosarcoma. The deadline for submission is October 31, 2024. Off-cycle applications may be considered on a case-by-case basis. You may find more information here: https://osinst.org/researchers/#grants.
